TP53 and acute myeloid leukemia: In this study, age (HR: 2.338, 95% CI: 1.065–5.133, p = 0.034), TP53 mutation status (HR: 5.647, 95% CI: 1.085–29.39, p = 0.040), and EVI1 fusion gene status (HR: 18.35, 95% CI: 3.293–102.3, p = 0.001) were also found to be independent adverse prognostic factors for AML, while the presence of the FLT3‐ITD mutation and a high white blood cell count (WBC ≥ 100 × 109/L) were not.